Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 5 - 60 years old~* Fever (axillary temperature equal or higher than 37,5 °C) or history of fever in the previous 24 hours~* Monoinfection with P. falciparum, with parasitic density between 1,000 and 200,000 par/µl~* Informed consent provided by patient or parent or legal tutor~  • Exclusion criteria:~* Mixed malaria infection~* Pregnancy or breastfeeding to child ≤ 6 months of age~* One or more danger signs or any sign of severe or complicated malaria~* A concomitant severe disease~* History of treatment with mefloquine in the last 60 days or chloroquine, primaquine or quinine within the 14 days before the present episode~* History of neuropsychiatric disease~* History of hypersensitivity reactions to artemisinins or mefloquine~* History of splenectomy

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dihydroartemisin-piperaquine (Type: EXPERIMENTAL): Dihydroartemisin-piperaquine (Artekin, Hualijian Pharmaceutical Co. Ltd., Guangzhou, China). Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
- Mefloquine + Artesunate (MAS3) (Type: ACTIVE_COMPARATOR): The MAS3 regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).